New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2013
06:42 EDTAMPEAmpio modifies Ampion IND to include dose escalation run-in study
Ampio Pharmaceuticals announced that it's Phase III clinical study of Ampion for the treatment for osteoarthritis of the knee will include a dose-escalation run-in study as recommended by the FDA. Dr. Vaughan Clift, Ampio's Chief Regulatory Officer, noted "The company has modified the original study design to accommodate the FDA recommendations and submitted this upgraded IND study protocol for clearance to begin treating patients. A Clinical Research Organization has been engaged and multiple clinical sites have been selected that are ready to enroll patients in the study. The dose ranging run-in study will commence shortly and will include 320 patients in total comparing 4 ml to 10 ml injection using the WOMAC pain scale."
News For AMPE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
15:57 EDTAMPEAmpio says Optina benefit not significant vs. placebo, Bloomberg reports
Vaughan Lennox Clift, Chief Regulatory Affairs Officer of Ampio, told Bloomberg in a phone interview that Optina's benefit is not significant versus the placebo. Optina helped a group improve from baseline, Bloomberg adds. Clift also said the FDA may allow narrow sales with a post-market study.
08:08 EDTAMPEAmpio announces positive study results on Optima
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use